

Aciphex[®] is classified as a proton pump inhibitor that effectively suppresses gastric acid secretion while inhibiting enzyme activity during the last phase of stomach acid secretion. *Aciphex*[®] was launched in the United States in 1999 and is currently marketed in more than 90 countries worldwide, including Japan, the United Kingdom, and Germany. *Aciphex*[®] was discovered and developed by Eisai and is copromoted in the United States with PriCara[®], a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Safe Harbor Statement

This press release may contain so-called "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including claims and concerns about product safety and efficacy; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations. Also, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, entry of competitive products (both branded and generic), and failure to gain market acceptance. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Aciphex[®] is a registered trademark of Eisai Co., Ltd.

Coumadin[®] is a registered trademark of Bristol-Myers Squibb Pharma Company.

###